ACTU Actuate Therapeutics, Inc.

NASDAQ
$0.27

Actuate Therapeutics, Inc. (ACTU) is expected to report earnings on February 12, 2027, after the market close. The consensus earnings estimate is a loss of $0.18 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -19.3% since its last earnings release on November 13, 2026.

Actuate Therapeutics Beat Consensus Estimates
Earnings Date
4th Quarter, Dec 2026
Feb 12
Friday · After Close
Earnings Whisper
-
vs ($0.18)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.28

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Actuate Therapeutics, Inc.

Actuate Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers. The company's lead product includes elraglusib. Actuate Therapeutics Inc. is based in FORT WORTH, Texas.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.